Latest Insider Transactions at Cullinan Oncology, Inc. (CGEM)
This section provides a real-time view of insider transactions for Cullinan Oncology, Inc. (CGEM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Cullinan Oncology, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Cullinan Oncology, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 24
2024
|
Nadim Ahmed President and CEO |
SELL
Open market or private sale
|
Direct |
8,400
-3.09%
|
$92,400
$11.87 P/Share
|
|
Dec 18
2024
|
Jacquelyn L Sumer Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,482
-3.7%
|
$38,302
$11.41 P/Share
|
|
Dec 18
2024
|
Jeffrey Alan Jones Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,632
-3.9%
|
$50,952
$11.41 P/Share
|
|
Dec 18
2024
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,693
-4.49%
|
$51,623
$11.41 P/Share
|
|
Dec 12
2024
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,489
-3.23%
|
$41,868
$12.52 P/Share
|
|
Nov 05
2024
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
8,000
-6.9%
|
$120,000
$15.64 P/Share
|
|
Sep 05
2024
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
8,000
-6.45%
|
$144,000
$18.09 P/Share
|
|
Jul 05
2024
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
8,000
-6.06%
|
$128,000
$16.33 P/Share
|
|
Jul 01
2024
|
Jennifer Michaelson Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,360
+1.76%
|
$21,240
$9.0 P/Share
|
|
Jun 10
2024
|
Thomas Ebeling |
BUY
Exercise of conversion of derivative security
|
Direct |
18,450
+9.0%
|
$239,850
$13.0 P/Share
|
|
May 23
2024
|
Thomas Ebeling |
BUY
Grant, award, or other acquisition
|
Direct |
100,699
+22.31%
|
$805,592
$8.52 P/Share
|
|
May 07
2024
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,606
-4.15%
|
$168,180
$30.06 P/Share
|
|
May 07
2024
|
Jennifer Michaelson Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,606
+3.98%
|
$22,424
$4.3 P/Share
|
|
May 06
2024
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
58,000
-16.82%
|
$1,624,000
$28.18 P/Share
|
|
May 06
2024
|
Jennifer Michaelson Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+21.05%
|
$200,000
$4.3 P/Share
|
|
Feb 22
2024
|
Jennifer Michaelson Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+26.66%
|
-
|
|
Feb 22
2024
|
Jeffrey Alan Jones Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+34.49%
|
-
|
|
Feb 22
2024
|
Nadim Ahmed President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
160,000
+37.08%
|
-
|
|
Feb 22
2024
|
Corrine Savill Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+15.56%
|
-
|
|
Feb 22
2024
|
Jacquelyn L Sumer Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+34.69%
|
-
|
|
Feb 22
2024
|
Jeffrey Trigilio Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+27.19%
|
-
|
|
Feb 01
2024
|
Corrine Savill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
40,000
-19.42%
|
$640,000
$16.18 P/Share
|
|
Feb 01
2024
|
Corrine Savill Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+16.26%
|
$160,000
$4.3 P/Share
|
|
Jan 29
2024
|
Corrine Savill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
40,000
-19.42%
|
$560,000
$14.09 P/Share
|
|
Jan 29
2024
|
Corrine Savill Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+16.26%
|
$160,000
$4.3 P/Share
|
|
Jan 23
2024
|
Corrine Savill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
21,316
-11.38%
|
$255,792
$12.46 P/Share
|
|
Jan 23
2024
|
Corrine Savill Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,316
+10.22%
|
$85,264
$4.3 P/Share
|
|
Jan 22
2024
|
Corrine Savill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
18,684
-5.15%
|
$224,208
$12.1 P/Share
|
|
Jan 22
2024
|
Corrine Savill Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,559
+7.31%
|
$58,236
$4.3 P/Share
|
|
Dec 26
2023
|
Nadim Ahmed President and CEO |
SELL
Open market or private sale
|
Direct |
4,272
-3.69%
|
$38,448
$9.24 P/Share
|
|
Dec 21
2023
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,145
-1.29%
|
$9,160
$8.5 P/Share
|
|
Dec 21
2023
|
Jeffrey Trigilio Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,920
-2.24%
|
$15,360
$8.5 P/Share
|
|
Dec 21
2023
|
Jacquelyn L Sumer Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,400
-3.07%
|
$11,200
$8.5 P/Share
|
|
Dec 21
2023
|
Jeffrey Alan Jones Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,860
-3.2%
|
$14,880
$8.5 P/Share
|
|
Dec 18
2023
|
Jeffrey Trigilio Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
398
-0.46%
|
$3,184
$8.22 P/Share
|
|
Dec 18
2023
|
Jacquelyn L Sumer Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
290
-0.63%
|
$2,320
$8.22 P/Share
|
|
Dec 18
2023
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
238
-0.27%
|
$1,904
$8.22 P/Share
|
|
Dec 18
2023
|
Jeffrey Alan Jones Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
386
-0.66%
|
$3,088
$8.22 P/Share
|
|
Dec 12
2023
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,068
-1.19%
|
$7,476
$7.81 P/Share
|
|
Dec 12
2023
|
Jeffrey Trigilio Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,926
-2.18%
|
$13,482
$7.81 P/Share
|
|
Jun 30
2023
|
Jeffrey Trigilio Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,340
+2.59%
|
$21,060
$9.08 P/Share
|
|
Jun 28
2023
|
Nadim Ahmed President and CEO |
SELL
Open market or private sale
|
Direct |
759
-0.65%
|
$8,349
$11.4 P/Share
|
|
Jun 20
2023
|
Jacquelyn L Sumer Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
291
-0.63%
|
$3,492
$12.94 P/Share
|
|
Jun 20
2023
|
Jeffrey Trigilio Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
399
-0.46%
|
$4,788
$12.94 P/Share
|
|
Jun 20
2023
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
238
-0.26%
|
$2,856
$12.94 P/Share
|
|
Jun 20
2023
|
Jeffrey Alan Jones Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
387
-0.66%
|
$4,644
$12.94 P/Share
|
|
Jun 12
2023
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
176
-0.19%
|
$2,288
$13.11 P/Share
|
|
Jun 12
2023
|
Jeffrey Trigilio Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
319
-0.37%
|
$4,147
$13.11 P/Share
|
|
Jun 07
2023
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
100
-0.11%
|
$1,200
$12.4 P/Share
|
|
Jun 07
2023
|
Jennifer Michaelson Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+0.11%
|
$400
$4.3 P/Share
|